Cargando…

Family history of cancer and gastroesophageal disorders and risk of esophageal and gastric adenocarcinomas: a case–control study

BACKGROUND: There is a paucity of data on familial risk of developing esophageal adenocarcinoma, gastric cardia adenocarcinoma and distal gastric adenocarcinoma from population-based studies. METHODS: A population-based case–control study of newly diagnosed gastroesophageal adenocarcinoma was conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Xuejuan, Tseng, Chiu-Chen, Bernstein, Leslie, Wu, Anna H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915076/ https://www.ncbi.nlm.nih.gov/pubmed/24495377 http://dx.doi.org/10.1186/1471-2407-14-60

Ejemplares similares

Gastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON)
por: Cook, Michael B., et al.
Publicado: (2014)

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study
por: Pape, Marieke, et al.
Publicado: (2023)

Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China
por: Gao, Ying, et al.
Publicado: (2009)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences
por: Zander, Thomas, et al.
Publicado: (2022)

Correlation of the location of superficial Barrett’s esophageal adenocarcinoma (s-BEA) with the direction of gastroesophageal reflux
por: Omae, Masami, et al.
Publicado: (2016)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus
por: Gharahkhani, Puya, et al.
Publicado: (2016)

Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma – where do we stand?
por: Mikolašević, Ivana, et al.
Publicado: (2018)

The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
por: van Hootegem, Sander J. M., et al.
Publicado: (2019)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma
por: Dzinic, Sijana H., et al.
Publicado: (2019)

Family history and the risk of gastric cancer
por: Yaghoobi, M, et al.
Publicado: (2010)

Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy
por: Badgwell, Brian, et al.
Publicado: (2017)

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
por: Ballhausen, Alexej, et al.
Publicado: (2022)

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer
por: Ahmad, M. Usman, et al.
Publicado: (2022)

Family history of esophageal cancer increases the risk of esophageal squamous cell carcinoma
por: Chen, Tiantian, et al.
Publicado: (2015)

AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas
por: Ghosh, Pradipta, et al.
Publicado: (2022)

Epigenetic Subgroups of Esophageal and Gastric Adenocarcinoma with Differential GATA5 DNA Methylation Associated with Clinical and Lifestyle Factors
por: Wang, Xinhui, et al.
Publicado: (2011)

Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma
por: Wennerström, E. Christina M., et al.
Publicado: (2016)

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2023)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
por: Walden, Daniel, et al.
Publicado: (2021)

PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma
por: Hußtegge, Marlon, et al.
Publicado: (2021)

Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
por: Schulz, Christoph, et al.
Publicado: (2020)

Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
por: Perkhofer, Lukas, et al.
Publicado: (2019)

Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
por: Businello, Gianluca, et al.
Publicado: (2022)

Association of Esophageal Inflammation, Obesity and Gastroesophageal Reflux Disease: From FDG PET/CT Perspective
por: Wu, Yen-Wen, et al.
Publicado: (2014)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Customization of therapy for gastroesophageal adenocarcinoma patients
por: Mizrak Kaya, Dilsa, et al.
Publicado: (2018)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Passive smoking and risk of oesophageal and gastric adenocarcinomas
por: Duan, L, et al.
Publicado: (2009)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ldhuu210hsnj2bclo3oqden4nj